78 results
8-K
EX-4.1
GLUE
Monte Rosa Therapeutics Inc
16 May 24
Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering
4:06pm
, the purpose of the foregoing is to subject collectively the Holder and all other Attribution Parties to the Maximum Percentage.
(c) “Closing Sale Price” means … for that purpose (the “Warrant Register”), in the name of the record Holder (which shall include the initial Holder or, as the case may be, any assignee
8-K
EX-1.1
GLUE
Monte Rosa Therapeutics Inc
16 May 24
Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering
4:06pm
by the Commission. No order suspending the effectiveness of the Registration Statement has been issued by the Commission, and no proceeding for that purpose … for that purpose or pursuant to Section 8A of the Securities Act; (vi) of the occurrence of any event or development within the Prospectus Delivery Period
424B5
GLUE
Monte Rosa Therapeutics Inc
16 May 24
Prospectus supplement for primary offering
4:04pm
for that purpose, subject to any preferential dividend rights of any outstanding preferred stock. Our common stock has no preemptive rights, conversion rights … on our common stock to “foreign financial institutions” (which is broadly defined for this purpose and in general includes investment vehicles
424B5
GLUE
Monte Rosa Therapeutics Inc
15 May 24
Prospectus supplement for primary offering
4:04pm
common stock are entitled to receive ratably any dividends declared by our board of directors out of funds legally available for that purpose, subject … to “foreign financial institutions” (which is broadly defined for this purpose and in general includes investment vehicles) and certain other Non-U.S
8-K
EX-99.2
dzfdi 9gbl
9 May 24
Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
7:05am
S-8
btfl6kq5h y4ccl7eyb8
14 Mar 24
Registration of securities for employees
4:08pm
8-K
EX-99.2
gw1b49
14 Mar 24
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
7:05am
8-K
EX-10.1
2rj9jq zi
26 Oct 23
Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq Rules
5:01pm
8-K
EX-4.1
hlfnpqwjk
26 Oct 23
Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq Rules
5:01pm
424B5
bibm9953qebkfus4oem
26 Oct 23
Prospectus supplement for primary offering
4:55pm
8-K
EX-99.4
dqlet p7d0eod
17 Oct 23
Monte Rosa to receive an upfront payment of $50 million and potential future payments exceeding $2 billion
7:55am